Completed PHASE2 INTERVENTIONAL 3-arm NCT01015235

Safety and Efficacy Study of KAI-1678 to Treat Subjects With Postoperative Pain

A Double-Blind, Randomized, Placebo- and Active-Comparator-Controlled, Single-Dose Study to Assess the Efficacy of KAI-1678 Administered by Subcutaneous Infusion for the Treatment of Postoperative Pain

Sponsor: KAI Pharmaceuticals

Conditions Pain, Postoperative

Interventions KAI-1678 Ketorolac Tromethamine Placebo

Updated 5 times since 2017 Last updated: Aug 31, 2011 Started: Dec 31, 2008 Primary completion: Feb 28, 2010 Completion: Feb 28, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01015235, this PHASE2 trial focuses on Pain, Postoperative and remains completed. Sponsored by KAI Pharmaceuticals, it has been updated 5 times since 2008, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Dec 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

KAI Pharmaceuticals
Trident Clinical Research Pty Ltd

Data source: KAI Pharmaceuticals

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Hamilton, New Zealand